A 2026 meta-analysis of 4 randomized trials found that GLP-1 receptor agonists reduced obstructive sleep apnea severity by 13.89 apnea-hypopnea events per hour compared with placebo, alongside 12.46 kg more weight loss than placebo.1 The effect looks clinically meaningful for obesity-linked sleep apnea, but high heterogeneity means the result should not be flattened into “GLP-1 …
A 2026 target-trial emulation involving 102,361 U.S. veterans with type 2 diabetes found no increased suicidality risk after starting semaglutide vs. sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors): suicidal ideation HR 0.99 and suicide attempt/death HR 1.05 after overlap weighting.1 That does not prove semaglutide prevents suicide, but it weakens the broad claim that semaglutide initiation itself …
GLP-1 drugs are usually described as appetite drugs, but a 2026 Nature mouse study mapped a more specific reward circuit: small-molecule GLP-1 receptor agonists suppressed palatable-food intake through Glp1r-expressing central-amygdala neurons that reduced dopamine release in the nucleus accumbens during high-fat-food retrieval.1 That mechanism makes binge-eating and substance-use hypotheses more plausible without turning an animal …
Semaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experiments. After 5 days of treatment, rats shifted away from cocaine choice without losing total operant responding, which separates the result from a broad appetite-suppression artifact. Research Highlights Semaglutide …